Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...

We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...

Today’s drop in Moderna’s price moves the company’s stock to its lowest levels since April 2020. Shares now trade 93% lower ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings reports from the nation's biggest banks.

China's trade surplus grew to $104.84 billion in December, as exports rose faster than expected, according to official customs data released on Monday. Chinese factories rushed to complete orders ...

The Biden administration is proposing a new framework for the exporting of the advanced computer chips used to develop artificial intelligence, an attempt to balance national security concerns ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...